The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

Novo Nordisk (NYSE: NVO) and Cava Group (NYSE: CAVA) are excellent choices. Novo Nordisk's shares have significantly lagged ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take ...

Patients have reported dental issues like tooth decay and dry mouth after taking GLP-1s like Ozempic for weight loss, though ...

In the marketing effort promoting Lilly’s Mounjaro, Stonestreet and his mother, Jamey, discuss living with type 2 diabetes and taking the GLP-1 for treatment.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...